Form 8-K - Current report:
SEC Accession No. 0001193125-26-065159
Filing Date
2026-02-24
Accepted
2026-02-24 06:30:26
Documents
13
Period of Report
2026-02-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pvla-20260224.htm   iXBRL 8-K 47393
2 PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON FEBRUARY 24, 2026 pvla-ex99_1.htm EX-99.1 45850
3 GRAPHIC img6060170_0.jpg GRAPHIC 19979
4 GRAPHIC img6060170_1.jpg GRAPHIC 794380
  Complete submission text file 0001193125-26-065159.txt   1330419

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pvla-20260224.xsd EX-101.SCH 26040
15 EXTRACTED XBRL INSTANCE DOCUMENT pvla-20260224_htm.xml XML 4710
Mailing Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087
Business Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Filer) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37471 | Film No.: 26667383
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)